

Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review

Description: Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company's operations and business divisions.
- Corporate strategy – Analyst's summarization of the company's business strategy.
- SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives' employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ipsen S.A. (Ipsen) is a specialty-driven pharmaceutical company. The company develops and markets drugs and therapeutic products. It provides specialty care drugs related to the areas of urology-oncology, endocrinology and neurology. The company also produces therapeutic products for the treatment of gastroenterological and neurological diseases. Its flagship products include specialty care therapeutics such as Decapeptyl for treatment of prostate cancer; and Somatuline indicated for the treatment of acromegaly and neuroendocrine tumors; and primary care products such as Smecta for treating acute and chronic diarrhea; and Florax for the treatment of constipation among others.

Ipsen S.A. Key Recent Developments

Mar 20, 2014: Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen's Share Capital via Private Placement

Feb 28, 2014: Ipsen's 2013 results and 2014 financial objectives

Feb 26, 2014: Ipsen Makes Strategic Move to Standardise on Veeva Systems' Cloud-based Content Management Solution to Increase Organisational Agility

Jan 10, 2014: Jonathan Barnsley Joins Ipsen as Executive Vice President, Technical Operations

Dec 12, 2013: Dominique Brard joins Ipsen as Executive Vice President, Human Resources

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you

track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Ipsen S.A. - Key Facts
Ipsen S.A. - Key Employees
Ipsen S.A. - Key Employee Biographies
Ipsen S.A. - Major Products and Services
Ipsen S.A. - Pharmaceutical Pipeline Products Data
Ipsen S.A., Pipeline Products by Therapy Area
Ipsen S.A., Pipeline Products by Development Phase
Ipsen S.A. - History
Ipsen S.A. - Company Statement
Ipsen S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Ipsen S.A. - Business Description
Ipsen S.A. - SWOT Analysis
SWOT Analysis - Overview
Ipsen S.A. - Strengths
Strength - Global Presence
Strength - Diversified Product Offerings
Strength - Increase in Sales
Ipsen S.A. - Weaknesses
Weakness - Dependence on Few Suppliers
Ipsen S.A. - Opportunities
Opportunity - Business Initiatives
Opportunity - Growth Prospects: Emerging Markets
Opportunity - Strong Product Pipeline
Ipsen S.A. - Threats
Threat - Growing Parallel Trade
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Ipsen S.A. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company's Lifesciences Financial Deals and Alliances

Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Ipsen S.A., Medical Equipment, Deals By Year, 2008 to YTD 2014
Ipsen S.A., Medical Equipment, Deals By Type, 2008 to YTD 2014
Ipsen S.A., Recent Deals Summary
Section 5 – Company’s Recent Developments
Ipsen S.A., Recent Developments
Mar 20, 2014: Ipsen Announces That Its Controlling Shareholder, Mayroy, Sold Approximately 7% of Ipsen’s Share Capital via Private Placement
Feb 28, 2014: Ipsen’s 2013 results and 2014 financial objectives
Feb 26, 2014: Ipsen Makes Strategic Move to Standardise on Veeva Systems’ Cloud-based Content Management Solution to Increase Organisational Agility
Jan 10, 2014: Jonathan Barnsley Joins Ipsen as Executive Vice President, Technical Operations
Dec 12, 2013: Dominique Brard joins Ipsen as Executive Vice President, Human Resources
Sep 26, 2013: Ipsen to Relocate US R&D Activities to Cambridge, MA in 2014
Jun 18, 2013: Daewoong Pharma Signs Contract Agreement With Ipsen To Export Smecta Suspension To China
Apr 25, 2013: Ipsen Reports Revenue Of €306.6m In Q1 2013
Jan 30, 2013: Ipsen Reports Revenue Of €294.9m In Q4 2012
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables

Ipsen S.A., Key Facts
Ipsen S.A., Key Employees
Ipsen S.A., Key Employee Biographies
Ipsen S.A., Major Products and Services
Ipsen S.A., Number of Pipeline Products by Therapy Area
Ipsen S.A., Number of Pipeline Products by Development Stage
Ipsen S.A., Pipeline Products By Therapy Area and Development Phase
Ipsen S.A., History
Ipsen S.A., Subsidiaries
Ipsen S.A., Key Competitors
Ipsen S.A., Ratios based on current share price
Ipsen S.A., Annual Ratios
Ipsen S.A., Interim Ratios
Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Ipsen S.A., Medical Equipment, Deals By Year, 2008 to YTD 2014
Ipsen S.A., Medical Equipment, Deals By Type, 2008 to YTD 2014
Ipsen S.A., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Ipsen S.A., Pipeline Products by Therapy Area
Ipsen S.A., Pipeline Products by Development Phase
Ipsen S.A., Performance Chart (2009 - 2013)
Ipsen S.A., Ratio Charts
Ipsen S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Ipsen S.A., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
Ipsen S.A., Medical Equipment, Deals By Year, 2008 to YTD 2014
Ipsen S.A., Medical Equipment, Deals by Type, 2008 to YTD 2014

RESEARCHANDMARKETS

Ordering: Order Online - <http://www.researchandmarkets.com/reports/1291924/>

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

<http://www.researchandmarkets.com/contact/>

Order Information

Please verify that the product information is correct and select the format(s) you require.

Product Name: Ipsen S.A. (IPN) - Financial and Strategic SWOT Analysis Review
Web Address: <http://www.researchandmarkets.com/reports/1291924/>
Office Code: SCUUBWHV

Product Formats

Please select the product formats and quantity you require:

	Quantity	
Electronic (PDF) - Single User:	<input type="checkbox"/>	EUR 102
Electronic (PDF) - Site License:	<input type="checkbox"/>	EUR 204
Electronic (PDF) - Enterprisewide:	<input type="checkbox"/>	EUR 307

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____ Last Name: _____

Email Address: * _____

Job Title: _____

Organisation: _____

Address: _____

City: _____

Postal / Zip Code: _____

Country: _____

Phone Number: _____

Fax Number: _____

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:
 - American Express
 - Diners Club
 - Master Card
 - Visa

Cardholder's Name _____

Cardholder's Signature _____

Expiry Date _____ | _____

Card Number _____

CVV Number _____

Issue Date _____ | _____

(for Diners Club only)

- Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

- Pay by wire transfer:

Please transfer funds to:

Account number	833 130 83
Sort code	98-53-30
Swift code	ULSBIE2D
IBAN number	IE78ULSB98533083313083
Bank Address	Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at <http://www.researchandmarkets.com/info/terms.asp>

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World